Novartis, DNDi to jointly develop LXE408 for visceral leishmaniasis

22 jul 2020

Share:

According to Novartis, more than a billion people across the world are at risk of being infected with leishmaniasis, which is transmitted by the bite of a sand-fly. Visceral leishmaniasis is the most serious form of leishmaniasis, which if left treated can lead to death.

Novartis said that treating visceral leishmaniasis is complex as it depends on the species of infecting parasite and the country, and also because treatment responses vary from region to region.

Read the full text here.

More articles